.
MergerLinks Header Logo

Announced

Sandoz to acquire the Japanese unit of Aspen Pharmacare for $440m.

Financials

Edit Data
Transaction Value£344m
Consideration TypeContingent Deferred Consideration, Cash
Capital Owned-
Capital Bid For100%
EV/Sales3.1x
EV/EBITDA16.4x
Share Price Premium-
One Off Charge-

Tags

Edit

Acquisition

Single Bidder

Private

Japan

Pending

pharmaceutical company

Pharmaceuticals

Majority

generic pharmaceuticals

Friendly

Synopsis

Edit

Sandoz, a division of Novartis, a Swiss multinational pharmaceutical company, agreed to acquire the Japanese unit of Aspen Pharmacare, a multinational South African holding company for pharmaceutical concerns, for $440m. Aspen’s portfolio in Japan consists of off-patent medicines with a focus on anesthetics and specialty brands. “The acquisition of Aspen’s Japanese operations would significantly strengthen our position in this country, a stable but growing generics market. We are committed to helping address patient and customer needs in the market as we aspire to become the world’s leading and most valued generics company,” Richard Saynor, Sandoz CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US